The 11th Annual Neuro-Oncology Review Course takes place November 11, the day before the SNO Annual Meeting & Education Day in Philadelphia. virtual.oxfordabstracts.com/…

ASFNR reinforced an important reality: reliable brain tumor response assessment requires imaging biomarkers that are quantitative, standardized, reproducible, and biologically validated. IB's proprietary and built-in technology #sRCBV available in IB Neuro provides automated, quantitative measurements without the variability associated with manually drawn normalization approaches. Building on this foundation, IB's #FTB maps remain the only tissue-validated solution supported by image-localized biopsy correlation to distinguish viable high-grade tumor from treatment effect. These are directly comparable across time - independent of scanner platform or field strength - enabling longitudinal reporting of treatment response. As quantitative imaging continues to evolve, the need for objective biomarkers that support patient care, clinical trials, and therapeutic development has never been greater. #ASFNR #BrainTumors #Neuroradiology #ImagingBiometrics #sRCBV #FTB

Great to see the growing recognition of advanced quantitative imaging (FTB) at #ASFNR2026. Thank you @Michael_Iv_MD for another great talk highlighting the importance of moving beyond anatomy alone. FTB mapping (automated with FTBx) represents a meaningful step toward more objective, personal, and quantitative assessment of brain tumor biology, treatment response, and clinical decision-making. #NeuroOncology #ImagingBiometrics #FTB

Great post! The enthusiasm around Fractional Tumor Burden (FTB) reinforces the growing need for objective imaging biomarkers in neuro-oncology. We're proud that Imaging Biometrics' FTB maps are helping clinicians tackle the challenge of progression versus pseudoprogression with greater confidence, automation, and quantification. #ASFNR26 #BrainTumor #NeuroOncology #FTB

"With IB Rad Tech, we can assess perfusion scans with greater confidence and gain a much clearer understanding of tumor heterogeneity. For both clinical practice and neuro-oncology research, this provides an additional layer of information. The excellent and responsive support from Imaging Biometrics makes the entire experience even more valuable." Thank you, Dr. Dylan Henssen, for sharing your experience! IB Rad Tech continues to support leading clinical and research programs today with customizable workflows that leverage IB's entire imaging ecosystem. Now, IB Vista builds on that foundation with a highly-configurable, platform-independent, workflow future (and with the same commitment to excellent support!). #NeuroOncology #MRI #MedicalImaging

Every advance against #Glioblastoma starts with clinical research and patient participation. We're encouraged to see studies like #GABLE exploring how advanced imaging MRI biomarkers are being used to help newly diagnosed patients with GBM. Wishing the investigators and patients every success! #ClinicalTrial #NeuroOncology #ImagingBiomarkers #FTB #IBNeuro

This is exactly the challenge advanced imaging was designed to address: moving beyond what can be seen visually on conventional MRI toward objective, quantitative biomarkers that better reflect what's happening within the tumor. We look forward to the results of the #GABLE trial. #GBM #BrainTumor #NeuroOncology #FTB #IBNeuro

Join our next IB User’s Group Webinar! 🧠 Quantitative Neuro-Imaging of Brain Tumors: From Standardized rCBV to Advanced Biomarker Workflows Featuring Kathleen Schmainda, PhD 📅 Oct. 6 | 1 PM CT mailchi.mp/imagingbiometrics…

Distinguishing tumor progression from treatment effect remains one of the most challenging problems in neuro-oncology. Quantitative biomarkers such as @ImgBiometrics' IB Neuro (standardized rCBV), IB DCE (permeability), IB Diffusion, and IB Delta T1 maps can provide objective insight beyond what conventional MRI alone can show. Thanks to Blackford for highlighting this important clinical challenge. #NeuroOncology #MRI #Radiology

Our September newsletter is out! Inside this issue: • The ECOG-ACRIN EAF223/GABLE glioblastoma imaging biomarker study • Kathleen Schmainda, PhD, at ESMRMB 2026 • Dr. Schmainda’s 2026 Hector F. DeLuca Scientific Achievement Award • IB Nimble 2 and connected multidisciplinary care • QSMetric™ and expanding access to quantitative susceptibility mapping • Where to find Imaging Biometrics at ASFNR 2026 Read the September issue: mailchi.mp/imagingbiometrics… #QuantitativeMRI #NeuroOncology #Glioblastoma #BrainTumorImaging #MedicalImaging #MRI #Neuroradiology #ImagingBiometrics

Looking forward to #ASFNR2026!

Looking forward to Dr. Yi Wang's EMTP 2026 presentation, "Overview of Clinical Applications of QSM." Dr. Wang's pioneering contributions have helped shape the field of QSM, and we're proud to work with him by offering QSMetric™, an FDA-cleared, automated, and patented platform, to advance quantitative imaging biomarkers in clinical practice. #QSM #QSMetric #MRI #EMTP2026

Excited to see Kathleen Schmainda, PhD, co-founder of @ImgBiometrics, speaking at the GliMR Pre-Day Lunch Symposium. A pioneer in quantitative neuroimaging and imaging biomarkers for brain tumors, Dr. Schmainda will discuss how advanced MRI techniques can bring greater objectivity to neuro-oncology care. #GliMR #NeuroOncology #MRI #BrainTumors #Radiology #ESMRMB

TWO PROGRAMS. ONE IMPORTANT IMAGING LESSON. Patients with recurrent glioblastoma received the same investigational therapy—but our ability to understand treatment response looked very different depending on the imaging available. The comparison between the GaM Phase 1 Clinical Trial and the Expanded Access Program highlights an important question: Are conventional imaging methods capturing the full picture of what is happening within an enhancing lesion? See how standardized DSC perfusion and Fractional Tumor Burden mapping helped reveal changes that may otherwise be difficult to measure over time. Read the full campaign: mailchi.mp/imagingbiometrics…

Radiologists tell us they appreciate not having to leave their normal workflow to generate advanced imaging results. With IB Clinic, standardized rCBV (IB Neuro) and Delta T1 maps are delivered automatically, eliminating the need for separate workstations, additional logins, and manual processing (normalization) steps. IT teams appreciate it too: fewer third-party systems to deploy, secure, maintain, and support. Advanced imaging. Simplified workflow. Quantitative output. #Neuroradiology #BrainTumor #MRI #HealthcareIT #ImagingBiometrics

Congratulations to Imaging Biometrics co-founder Dr. Kathleen Schmainda on receiving the 2026 Hector F. DeLuca Scientific Achievement Award from BioForward Wisconsin! A recognized leader in advanced MRI and brain tumor imaging, Dr. Schmainda's pioneering work has helped translate quantitative imaging research into routine clinical tools that support patient care worldwide. Her vision, scientific leadership, and commitment to innovation continue to establish new standards in advanced imaging and influence clinical decision making. #QuantitativeMRI #NeuroOncology #MedicalImaging #BioForward #ImagingBiometrics